Psoriasis, <scp>COVID</scp> ‐19, and acute respiratory distress syndrome: Focusing on the risk of concomitant biological treatment

Abstract

Dermatologic TherapyVolume 33, Issue 4 e13706 Letter Psoriasis, COVID-19, and acute respiratory distress syndrome: Focusing on the risk of concomitant biological treatment Michela Magnano, Corresponding Author Michela Magnano [email protected] orcid.org/0000-0001-9429-9004 Division of Dermatology, Psoriasis Outpatient Service, Santa Chiara Hospital, Trento, Italy Correspondence Michela Magnano, Division of Dermatology, Psoriasis Outpatient Service, Santa Chiara Hospital, Largo Medaglie d'Oro 9, 38122 Trento, Italy. Email: [email protected]Search for more papers by this authorRiccardo Balestri, Riccardo Balestri Division of Dermatology, Psoriasis Outpatient Service, Santa Chiara Hospital, Trento, ItalySearch for more papers by this authorFederico Bardazzi, Federico Bardazzi Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine University of Bologna, Bologna, ItalySearch for more papers by this authorCarlo Mazzatenta, Carlo Mazzatenta Division of Dermatology, San Luca Hospital, Lucca, ItalySearch for more papers by this authorCarlo R. Girardelli, Carlo R. Girardelli Division of Dermatology, Psoriasis Outpatient Service, Santa Chiara Hospital, Trento, ItalySearch for more papers by this authorGiulia Rech, Giulia Rech Division of Dermatology, Psoriasis Outpatient Service, Santa Chiara Hospital, Trento, ItalySearch for more papers by this author Michela Magnano, Corresponding Author Michela Magnano [email protected] orcid.org/0000-0001-9429-9004 Division of Dermatology, Psoriasis Outpatient Service, Santa Chiara Hospital, Trento, Italy Correspondence Michela Magnano, Division of Dermatology, Psoriasis Outpatient Service, Santa Chiara Hospital, Largo Medaglie d'Oro 9, 38122 Trento, Italy. Email: [email protected]Search for more papers by this authorRiccardo Balestri, Riccardo Balestri Division of Dermatology, Psoriasis Outpatient Service, Santa Chiara Hospital, Trento, ItalySearch for more papers by this authorFederico Bardazzi, Federico Bardazzi Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine University of Bologna, Bologna, ItalySearch for more papers by this authorCarlo Mazzatenta, Carlo Mazzatenta Division of Dermatology, San Luca Hospital, Lucca, ItalySearch for more papers by this authorCarlo R. Girardelli, Carlo R. Girardelli Division of Dermatology, Psoriasis Outpatient Service, Santa Chiara Hospital, Trento, ItalySearch for more papers by this authorGiulia Rech, Giulia Rech Division of Dermatology, Psoriasis Outpatient Service, Santa Chiara Hospital, Trento, ItalySearch for more papers by this author First published: 30 May 2020 https://doi.org/10.1111/dth.13706Citations: 14Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Gisondi P, Facheris P, Dapavo P, et al. The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. Br J Dermatol. 2020. [Online ahead of print]. https://doi.org/10.1111/bjd.19158. 10.1111/bjd.19158 Web of Science®Google Scholar 2Li C, Xu BH. The viral, epidemiologic, clinical characteristics and potential therapy options for COVID-19: a review. Eur Rev Med Pharmacol Sci. 2020; 24(8): 4576-4584. CASPubMedWeb of Science®Google Scholar 3Bardazzi F, Loi C, Sacchelli L, Di Altobrando A. Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. J Dermatolog Treat. 2020; 31(4): 320-321. https://doi.org/10.1080/09546634.2020.1749545. 10.1080/09546634.2020.1749545 CASPubMedWeb of Science®Google Scholar 4Riccardo F, Andrianou X, Bella A, Del Manso M, Urdiales AM, Fabiani M, et al. For Istituto Superiore di Sanità. 7th May 2020. Retrieved by https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_7-maggio-2020.pdf (last accessed May 14 2020). Google Scholar 5Grodner C, Sbidian E, Weill A, Mezzarobba M. Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database. J Eur Acad Dermatol Venereol. 2020. [Online ahead of print]. https://doi.org/10.1111/jdv.16566. 10.1111/jdv.16238 Web of Science®Google Scholar 6Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020; 82(5): 1217-1218. 10.1016/j.jaad.2020.03.031 CASPubMedWeb of Science®Google Scholar 7Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J Am Acad Dermatol. 2020; 82(5): e173-e175. 10.1016/j.jaad.2020.03.046 CASPubMedWeb of Science®Google Scholar 8Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. 2020; 395(10236): 1544-1545. https://doi.org/10.1016/S0140-6736(20)31024-2. 10.1016/S0140-6736(20)31024-2 CASPubMedWeb of Science®Google Scholar Citing Literature ReferencesRelatedInformation

Topics & Concepts